ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
4'-Methoxyresveratrol Improves Hepatic Insulin Resistance Induced by a High-Fat-Diet via Anti-Oxidative-Stress Activity.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity and a high-fat diet (HFD) are key factors contributing to hepatic fat accumulation and type 2 diabetes mellitus (T2DM). Research indicates that oxidative stress induced by HFD mediates hepatic insulin resistance (HIR) through mechanisms such as promoting inflammation and lipid accumulation. Given that 4'-methoxyresveratrol (4-MR) exhibits remarkable anti-inflammatory and antioxidant activities, it is of great research significance to explore whether it can effectively counteract HFD-induced HIR by enhancing antioxidant stress. Purpose: This study aimed to explore the effects of 4MR on liver oxidative damage and insulin sensitivity. Methods: Mice were fed a HFD for 8 weeks, followed by an intraperitoneal glucose tolerance test to assess insulin resistance. The in-vivo experiments were divided into three groups, including the control group, the HFD group, and the HFD + 4MR group. After 6 weeks of 4MR treatment, blood and liver samples were analyzed for biochemical markers, lipid peroxidation, antioxidant capacity, and liver protein levels. Insulin-resistant HepG2 cells were treated with 4MR and evaluated for proliferation and toxicity. Results: 4MR reduced fasting blood glucose and lipid levels, improved insulin sensitivity, and decreased liver malondialdehyde levels, while increasing catalase and antioxidant enzyme activities. In both mice and HepG2 cells, 4MR increased Sirt1, p-FOXO1, and CAT expression levels and decreased FOXO1 expression levels. Conclusion: 4MR alleviated hepatic oxidative stress, enhanced insulin sensitivity, and reduced glucose levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.